Bacil Pharma (524516) 주식 개요바실 파마는 인도에서 의약품, 의약 화학 제품 및 식물성 제품을 제조, 수출 및 소매하는 회사입니다. 자세히 보기524516 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적4/6재무 건전성4/6배당0/6강점지난 1년간 수익이 284.9% 증가했습니다.위험 분석의미 있는 시가총액이 없습니다(₹587M)수익이 USD$1m 미만입니다(₹0)모든 위험 점검 보기524516 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹40.92해당 없음내재 할인율Est. Revenue$PastFuture-39m16m2016201920222025202620282031Revenue ₹1.0Earnings ₹0AdvancedSet Fair ValueView all narrativesBacil Pharma Limited 경쟁사Kabra DrugsSymbol: BSE:524322Market cap: ₹546.7mVilin Bio MedSymbol: NSEI:VILINBIOMarket cap: ₹558.7mBiofil Chemicals and PharmaceuticalsSymbol: BSE:524396Market cap: ₹571.4mVasundhara RasayansSymbol: BSE:538634Market cap: ₹540.3m가격 이력 및 성과Bacil Pharma 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₹40.9252주 최고가₹61.8052주 최저가₹26.69베타0.331개월 변동-18.21%3개월 변동-14.27%1년 변동14.30%3년 변동361.85%5년 변동485.41%IPO 이후 변동1,301.37%최근 뉴스 및 업데이트Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹39.31, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 322% over the past three years.공시 • May 11Bacil Pharma Limited to Report Q4, 2026 Results on May 22, 2026Bacil Pharma Limited announced that they will report Q4, 2026 results on May 22, 2026New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m (₹5.5m revenue, or US$60k). Market cap is less than US$10m (₹694.0m market cap, or US$7.59m). Minor Risk Large one-off items impacting financial results.공시 • Feb 05Bacil Pharma Limited to Report Q3, 2026 Results on Feb 13, 2026Bacil Pharma Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Jan 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹626.7m market cap, or US$6.94m). Minor Risk Large one-off items impacting financial results.공시 • Nov 05Bacil Pharma Limited to Report Q2, 2026 Results on Nov 13, 2025Bacil Pharma Limited announced that they will report Q2, 2026 results on Nov 13, 2025더 많은 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹39.31, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 322% over the past three years.공시 • May 11Bacil Pharma Limited to Report Q4, 2026 Results on May 22, 2026Bacil Pharma Limited announced that they will report Q4, 2026 results on May 22, 2026New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m (₹5.5m revenue, or US$60k). Market cap is less than US$10m (₹694.0m market cap, or US$7.59m). Minor Risk Large one-off items impacting financial results.공시 • Feb 05Bacil Pharma Limited to Report Q3, 2026 Results on Feb 13, 2026Bacil Pharma Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Jan 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹626.7m market cap, or US$6.94m). Minor Risk Large one-off items impacting financial results.공시 • Nov 05Bacil Pharma Limited to Report Q2, 2026 Results on Nov 13, 2025Bacil Pharma Limited announced that they will report Q2, 2026 results on Nov 13, 2025Valuation Update With 7 Day Price Move • Nov 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹32.83, the stock trades at a trailing P/E ratio of 42.6x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 394% over the past three years.공시 • Sep 05Bacil Pharma Limited, Annual General Meeting, Sep 29, 2025Bacil Pharma Limited, Annual General Meeting, Sep 29, 2025, at 13:00 Indian Standard Time.공시 • Aug 06Bacil Pharma Limited to Report Q1, 2026 Results on Aug 12, 2025Bacil Pharma Limited announced that they will report Q1, 2026 results on Aug 12, 2025Board Change • Aug 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Non-Executive Independent Director Avani Godhaniya is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • May 18Bacil Pharma Limited to Report Q4, 2025 Results on May 26, 2025Bacil Pharma Limited announced that they will report Q4, 2025 results on May 26, 2025New Risk • May 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 144% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹594.2m market cap, or US$7.03m). Minor Risks Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹12m sold).Recent Insider Transactions • Mar 25Executive Director recently sold ₹7.9m worth of stockOn the 21st of March, Prakash Shah sold around 208k shares on-market at roughly ₹38.00 per share. This transaction amounted to 99% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹16m more than they bought in the last 12 months.Recent Insider Transactions • Mar 12Executive Director recently sold ₹4.1m worth of stockOn the 10th of March, Prakash Shah sold around 115k shares on-market at roughly ₹35.89 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹8.1m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹47.88, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 404% over the past three years.공시 • Jan 13Bacil Pharma Limited to Report Q3, 2025 Results on Jan 21, 2025Bacil Pharma Limited announced that they will report Q3, 2025 results on Jan 21, 2025공시 • Oct 17+ 1 more updateBacil Pharma Limited announced that it expects to receive INR 50 million in fundingBacil Pharma Limited announced a private placement to issue 1,562,500 shares at an issue price of INR 32 per share for the gross proceeds of INR 50,000,000 on October 15, 2024. The transaction will include participation from proposed public allottees (Category Non-Promoter). the transaction has been approved by shareholders and subject to approval of members of the company in the ensuing Extra-Ordinary General Meeting and other regulatory approvals from authorities.공시 • Oct 16Bacil Pharma Limited to Report Q2, 2025 Results on Oct 23, 2024Bacil Pharma Limited announced that they will report Q2, 2025 results on Oct 23, 2024Recent Insider Transactions • Sep 24Executive Director recently sold ₹4.0m worth of stockOn the 20th of September, Prakash Shah sold around 157k shares on-market at roughly ₹25.63 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.공시 • Sep 10Bacil Pharma Limited, Annual General Meeting, Sep 27, 2024Bacil Pharma Limited, Annual General Meeting, Sep 27, 2024, at 10:00 Indian Standard Time. Location: 71, laxmi building, 4th floor, sir p m road, fort, mumbai-400001, mumbai IndiaBoard Change • Sep 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent Non-Executive Director Lalit Jain was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Aug 31Bacil Pharma Limited Announces Resignation Suman Prakash Shah as Non-Executive DirectorBacil Pharma Limited announced that at the board meeting held on August 31, 2024, approved resignation of Mrs. Suman Prakash Shah as Non-Executive Director of the Company with effect from August 31, 2024 due to pre-occupancy in other assignments and personal. reasons. Names of Listed Entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any. 1. Directorship -Sanmitra Commercia Limited 2. Membership/Chairmanship in Board Committees- NIL.공시 • Aug 08Bacil Pharma Limited to Report Q1, 2025 Results on Aug 14, 2024Bacil Pharma Limited announced that they will report Q1, 2025 results on Aug 14, 2024공시 • May 17Bacil Pharma Limited to Report Q4, 2024 Results on May 21, 2024Bacil Pharma Limited announced that they will report Q4, 2024 results on May 21, 2024New Risk • Nov 13New major risk - Revenue and earnings growthEarnings have declined by 0.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 0.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (₹46.8m market cap, or US$561.2k).공시 • Nov 04Bacil Pharma Limited to Report Q2, 2024 Results on Nov 10, 2023Bacil Pharma Limited announced that they will report Q2, 2024 results on Nov 10, 2023공시 • Sep 15Bacil Pharma Limited Appoints Mrs. Bhavana Tak as Company Secretary and Compliance OfficerBoard of Directors of Bacil Pharma Limited at their meeting held on 14 th September, 2023 transacted the following Business: Considered and approved appointment of Mrs. Bhavana Tak (ACS No- A71532) as Company Secretary and Compliance Officer of the Company based on recommendation by Nomination and Remuneration Committee. Mrs. Bhavana Tak is a Qualified Company Secretary and having work Experience undera PCS Firm.공시 • Aug 25Bacil Pharma Limited, Annual General Meeting, Sep 16, 2023Bacil Pharma Limited, Annual General Meeting, Sep 16, 2023, at 14:00 Indian Standard Time. Location: 71, Laxmi Building, 4th Floor, Sir P. M. Road Fort Mumbai India Agenda: To receive, consider and adopt the Audited Financial Statements of the Company as at 31st March, 2023 and Reports of the Directors' and Auditor's thereon; to appoint a Director in place of Mr. Prakash Bhoorchand Shah who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment; and to consider other matter.공시 • Aug 08Bacil Pharma Limited to Report Q1, 2024 Results on Aug 14, 2023Bacil Pharma Limited announced that they will report Q1, 2024 results on Aug 14, 2023공시 • Feb 03Bacil Pharma Limited to Report Q3, 2023 Results on Feb 11, 2023Bacil Pharma Limited announced that they will report Q3, 2023 results on Feb 11, 2023Board Change • Oct 31High number of new directorsNon-Executive & Non-Independent Director Suman Shah was the last director to join the board, commencing their role in 2022.공시 • Sep 30Bacil Pharma Limited Appoints Suman Shah as Non-Executive Non- Independent DirectorBacil Pharma Limited appointed Suman Shah (DIN: 01764668), as Non-Executive Non- Independent Director of the Company at its AGM held on September 29, 2022.공시 • Sep 02Bacil Pharma Limited, Annual General Meeting, Sep 29, 2022Bacil Pharma Limited, Annual General Meeting, Sep 29, 2022. Agenda: To consider and approve re-appointment of M/s Laxmikant Kabra & Co, LLP as Statutory Auditors of the Company for the second term of Five Years from Financial Year 2022-23 up to Financial Year 2026-27; to consider and approve appointment of Mrs. Suman Shah as Non-Executive Non-Independent Director of the Company; and to consider other matters.공시 • May 23Bacil Pharma Limited to Report Q4, 2022 Results on May 30, 2022Bacil Pharma Limited announced that they will report Q4, 2022 results on May 30, 2022Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Mar 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Feb 06Bacil Pharma Limited to Report Q3, 2022 Results on Feb 14, 2022Bacil Pharma Limited announced that they will report Q3, 2022 results on Feb 14, 2022Board Change • Sep 13Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Lalit Jain was the last independent director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Is New 90 Day High Low • Mar 05New 90-day low: ₹4.53The company is down 19% from its price of ₹5.60 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.공시 • Feb 06Bacil Pharma Limited to Report Q3, 2021 Results on Feb 13, 2021Bacil Pharma Limited announced that they will report Q3, 2021 results on Feb 13, 2021Is New 90 Day High Low • Dec 31New 90-day low: ₹4.72The company is down 9.0% from its price of ₹5.20 on 01 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period.공시 • Oct 20Bacil Pharma Limited Announces Appointment of Vaishali Vaghasiya as Company Secretary and Compliance OfficerBacil Pharma Limited announced that Ms. Vaishali Vaghasiya (A-60980) a qualified member of Institute of Company Secretary of India is been appointed as Company Secretary and Compliance Officer of the company with effect from 19 October, 2020, pursuant to Section 203 of the Companies Act 2013 and Regulation 6(1) of the Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015.Is New 90 Day High Low • Sep 22New 90-day high: ₹3.74The company is up 44% from its price of ₹2.60 on 24 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 14% over the same period.공시 • Sep 12Bacil Pharma Limited to Report Q1, 2021 Results on Sep 15, 2020Bacil Pharma Limited announced that they will report Q1, 2021 results on Sep 15, 2020공시 • Jul 26Bacil Pharma Limited to Report Q4, 2020 Results on Jul 30, 2020Bacil Pharma Limited announced that they will report Q4, 2020 results on Jul 30, 2020주주 수익률524516IN PharmaceuticalsIN 시장7D2.3%1.1%-1.0%1Y14.3%10.2%-2.4%전체 주주 수익률 보기수익률 대 산업: 524516은 지난 1년 동안 10.2%의 수익을 기록한 Indian Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 524516은 지난 1년 동안 -2.4%를 기록한 Indian 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is 524516's price volatile compared to industry and market?524516 volatility524516 Average Weekly Movement8.2%Pharmaceuticals Industry Average Movement7.1%Market Average Movement6.8%10% most volatile stocks in IN Market9.9%10% least volatile stocks in IN Market4.4%안정적인 주가: 524516는 지난 3개월 동안 Indian 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 524516의 주간 변동성(8%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트19872Ganpat Salekarbacilpharma.co.in바실 파마는 인도에서 의약품, 의약 화학 제품 및 식물성 제품을 제조, 수출 및 소매하는 회사입니다. 이 회사는 항불안제, 항히스타민제, 화합물, 약물, 허브 정제 및 캡슐을 제공합니다. 바실 파마는 1987년에 설립되었으며 인도 뭄바이에 본사를 두고 있습니다.더 보기Bacil Pharma Limited 기초 지표 요약Bacil Pharma의 순이익과 매출은 시가총액과 어떻게 비교됩니까?524516 기초 통계시가총액₹587.32m순이익 (TTM)₹15.56m매출 (TTM)n/a37.8x주가수익비율(P/E)0.0x주가매출비율(P/S)524516는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표524516 손익계산서 (TTM)매출₹0매출원가₹0총이익₹0기타 비용-₹15.55m순이익₹15.56m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)1.08총이익률0.00%순이익률0.00%부채/자본 비율0%524516의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/29 19:28종가2026/06/29 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bacil Pharma Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹39.31, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 322% over the past three years.
공시 • May 11Bacil Pharma Limited to Report Q4, 2026 Results on May 22, 2026Bacil Pharma Limited announced that they will report Q4, 2026 results on May 22, 2026
New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m (₹5.5m revenue, or US$60k). Market cap is less than US$10m (₹694.0m market cap, or US$7.59m). Minor Risk Large one-off items impacting financial results.
공시 • Feb 05Bacil Pharma Limited to Report Q3, 2026 Results on Feb 13, 2026Bacil Pharma Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Jan 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹626.7m market cap, or US$6.94m). Minor Risk Large one-off items impacting financial results.
공시 • Nov 05Bacil Pharma Limited to Report Q2, 2026 Results on Nov 13, 2025Bacil Pharma Limited announced that they will report Q2, 2026 results on Nov 13, 2025
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹39.31, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 322% over the past three years.
공시 • May 11Bacil Pharma Limited to Report Q4, 2026 Results on May 22, 2026Bacil Pharma Limited announced that they will report Q4, 2026 results on May 22, 2026
New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m (₹5.5m revenue, or US$60k). Market cap is less than US$10m (₹694.0m market cap, or US$7.59m). Minor Risk Large one-off items impacting financial results.
공시 • Feb 05Bacil Pharma Limited to Report Q3, 2026 Results on Feb 13, 2026Bacil Pharma Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Jan 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹626.7m market cap, or US$6.94m). Minor Risk Large one-off items impacting financial results.
공시 • Nov 05Bacil Pharma Limited to Report Q2, 2026 Results on Nov 13, 2025Bacil Pharma Limited announced that they will report Q2, 2026 results on Nov 13, 2025
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹32.83, the stock trades at a trailing P/E ratio of 42.6x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 394% over the past three years.
공시 • Sep 05Bacil Pharma Limited, Annual General Meeting, Sep 29, 2025Bacil Pharma Limited, Annual General Meeting, Sep 29, 2025, at 13:00 Indian Standard Time.
공시 • Aug 06Bacil Pharma Limited to Report Q1, 2026 Results on Aug 12, 2025Bacil Pharma Limited announced that they will report Q1, 2026 results on Aug 12, 2025
Board Change • Aug 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Non-Executive Independent Director Avani Godhaniya is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • May 18Bacil Pharma Limited to Report Q4, 2025 Results on May 26, 2025Bacil Pharma Limited announced that they will report Q4, 2025 results on May 26, 2025
New Risk • May 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 144% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹594.2m market cap, or US$7.03m). Minor Risks Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹12m sold).
Recent Insider Transactions • Mar 25Executive Director recently sold ₹7.9m worth of stockOn the 21st of March, Prakash Shah sold around 208k shares on-market at roughly ₹38.00 per share. This transaction amounted to 99% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹16m more than they bought in the last 12 months.
Recent Insider Transactions • Mar 12Executive Director recently sold ₹4.1m worth of stockOn the 10th of March, Prakash Shah sold around 115k shares on-market at roughly ₹35.89 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹8.1m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹47.88, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 404% over the past three years.
공시 • Jan 13Bacil Pharma Limited to Report Q3, 2025 Results on Jan 21, 2025Bacil Pharma Limited announced that they will report Q3, 2025 results on Jan 21, 2025
공시 • Oct 17+ 1 more updateBacil Pharma Limited announced that it expects to receive INR 50 million in fundingBacil Pharma Limited announced a private placement to issue 1,562,500 shares at an issue price of INR 32 per share for the gross proceeds of INR 50,000,000 on October 15, 2024. The transaction will include participation from proposed public allottees (Category Non-Promoter). the transaction has been approved by shareholders and subject to approval of members of the company in the ensuing Extra-Ordinary General Meeting and other regulatory approvals from authorities.
공시 • Oct 16Bacil Pharma Limited to Report Q2, 2025 Results on Oct 23, 2024Bacil Pharma Limited announced that they will report Q2, 2025 results on Oct 23, 2024
Recent Insider Transactions • Sep 24Executive Director recently sold ₹4.0m worth of stockOn the 20th of September, Prakash Shah sold around 157k shares on-market at roughly ₹25.63 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
공시 • Sep 10Bacil Pharma Limited, Annual General Meeting, Sep 27, 2024Bacil Pharma Limited, Annual General Meeting, Sep 27, 2024, at 10:00 Indian Standard Time. Location: 71, laxmi building, 4th floor, sir p m road, fort, mumbai-400001, mumbai India
Board Change • Sep 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent Non-Executive Director Lalit Jain was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Aug 31Bacil Pharma Limited Announces Resignation Suman Prakash Shah as Non-Executive DirectorBacil Pharma Limited announced that at the board meeting held on August 31, 2024, approved resignation of Mrs. Suman Prakash Shah as Non-Executive Director of the Company with effect from August 31, 2024 due to pre-occupancy in other assignments and personal. reasons. Names of Listed Entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any. 1. Directorship -Sanmitra Commercia Limited 2. Membership/Chairmanship in Board Committees- NIL.
공시 • Aug 08Bacil Pharma Limited to Report Q1, 2025 Results on Aug 14, 2024Bacil Pharma Limited announced that they will report Q1, 2025 results on Aug 14, 2024
공시 • May 17Bacil Pharma Limited to Report Q4, 2024 Results on May 21, 2024Bacil Pharma Limited announced that they will report Q4, 2024 results on May 21, 2024
New Risk • Nov 13New major risk - Revenue and earnings growthEarnings have declined by 0.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 0.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (₹46.8m market cap, or US$561.2k).
공시 • Nov 04Bacil Pharma Limited to Report Q2, 2024 Results on Nov 10, 2023Bacil Pharma Limited announced that they will report Q2, 2024 results on Nov 10, 2023
공시 • Sep 15Bacil Pharma Limited Appoints Mrs. Bhavana Tak as Company Secretary and Compliance OfficerBoard of Directors of Bacil Pharma Limited at their meeting held on 14 th September, 2023 transacted the following Business: Considered and approved appointment of Mrs. Bhavana Tak (ACS No- A71532) as Company Secretary and Compliance Officer of the Company based on recommendation by Nomination and Remuneration Committee. Mrs. Bhavana Tak is a Qualified Company Secretary and having work Experience undera PCS Firm.
공시 • Aug 25Bacil Pharma Limited, Annual General Meeting, Sep 16, 2023Bacil Pharma Limited, Annual General Meeting, Sep 16, 2023, at 14:00 Indian Standard Time. Location: 71, Laxmi Building, 4th Floor, Sir P. M. Road Fort Mumbai India Agenda: To receive, consider and adopt the Audited Financial Statements of the Company as at 31st March, 2023 and Reports of the Directors' and Auditor's thereon; to appoint a Director in place of Mr. Prakash Bhoorchand Shah who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment; and to consider other matter.
공시 • Aug 08Bacil Pharma Limited to Report Q1, 2024 Results on Aug 14, 2023Bacil Pharma Limited announced that they will report Q1, 2024 results on Aug 14, 2023
공시 • Feb 03Bacil Pharma Limited to Report Q3, 2023 Results on Feb 11, 2023Bacil Pharma Limited announced that they will report Q3, 2023 results on Feb 11, 2023
Board Change • Oct 31High number of new directorsNon-Executive & Non-Independent Director Suman Shah was the last director to join the board, commencing their role in 2022.
공시 • Sep 30Bacil Pharma Limited Appoints Suman Shah as Non-Executive Non- Independent DirectorBacil Pharma Limited appointed Suman Shah (DIN: 01764668), as Non-Executive Non- Independent Director of the Company at its AGM held on September 29, 2022.
공시 • Sep 02Bacil Pharma Limited, Annual General Meeting, Sep 29, 2022Bacil Pharma Limited, Annual General Meeting, Sep 29, 2022. Agenda: To consider and approve re-appointment of M/s Laxmikant Kabra & Co, LLP as Statutory Auditors of the Company for the second term of Five Years from Financial Year 2022-23 up to Financial Year 2026-27; to consider and approve appointment of Mrs. Suman Shah as Non-Executive Non-Independent Director of the Company; and to consider other matters.
공시 • May 23Bacil Pharma Limited to Report Q4, 2022 Results on May 30, 2022Bacil Pharma Limited announced that they will report Q4, 2022 results on May 30, 2022
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Mar 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Feb 06Bacil Pharma Limited to Report Q3, 2022 Results on Feb 14, 2022Bacil Pharma Limited announced that they will report Q3, 2022 results on Feb 14, 2022
Board Change • Sep 13Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Lalit Jain was the last independent director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Is New 90 Day High Low • Mar 05New 90-day low: ₹4.53The company is down 19% from its price of ₹5.60 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
공시 • Feb 06Bacil Pharma Limited to Report Q3, 2021 Results on Feb 13, 2021Bacil Pharma Limited announced that they will report Q3, 2021 results on Feb 13, 2021
Is New 90 Day High Low • Dec 31New 90-day low: ₹4.72The company is down 9.0% from its price of ₹5.20 on 01 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period.
공시 • Oct 20Bacil Pharma Limited Announces Appointment of Vaishali Vaghasiya as Company Secretary and Compliance OfficerBacil Pharma Limited announced that Ms. Vaishali Vaghasiya (A-60980) a qualified member of Institute of Company Secretary of India is been appointed as Company Secretary and Compliance Officer of the company with effect from 19 October, 2020, pursuant to Section 203 of the Companies Act 2013 and Regulation 6(1) of the Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015.
Is New 90 Day High Low • Sep 22New 90-day high: ₹3.74The company is up 44% from its price of ₹2.60 on 24 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 14% over the same period.
공시 • Sep 12Bacil Pharma Limited to Report Q1, 2021 Results on Sep 15, 2020Bacil Pharma Limited announced that they will report Q1, 2021 results on Sep 15, 2020
공시 • Jul 26Bacil Pharma Limited to Report Q4, 2020 Results on Jul 30, 2020Bacil Pharma Limited announced that they will report Q4, 2020 results on Jul 30, 2020
